TY - JOUR
T1 - SARS-CoV-2 susceptibility and ACE2 gene variations within diverse ethnic backgrounds
AU - Vadgama, Nirmal
AU - Kreymerman, Alexander
AU - Campbell, Jackie
AU - Shamardina, Olga
AU - Brugger, Christiane
AU - Genomics England Research Consortium,
AU - Deaconescu, Alexandra
AU - Lee, Richard T
AU - Penkett, Christopher J
AU - Gifford, Casey A
AU - Mercola, Mark
AU - Nasir, Jamal
AU - Karakikes, Ionnis
N1 - Copyright © 2022 Vadgama, Kreymerman, Campbell, Shamardina, Brugger, Research Consortium, Deaconescu, Lee, Penkett, Gifford, Mercola, Nasir and Karakikes.
PY - 2022/4/27
Y1 - 2022/4/27
N2 - There is considerable variability in the susceptibility and progression for COVID-19 and it appears to be strongly correlated with
age, gender, ethnicity and pre-existing health conditions. However, to our knowledge, cohort studies of COVID-19 in clinically
vulnerable groups are lacking. Host genetics has also emerged as a major risk factor for COVID-19, and variation in the ACE2
receptor, which facilitates entry of the SARS-CoV-2 virus into the cell, has become a major focus of attention. Thus, we
interrogated an ethnically diverse cohort of National Health Service (NHS) patients in the United Kingdom (UK) to assess the
association between variants in the ACE2 locus and COVID-19 risk. We analysed whole-genome sequencing (WGS) data of 1,837 cases
who were tested positive for SARS-CoV-2, and 37,207 controls who were not tested, from the UK’s 100,000 Genomes Project
(100KGP) for the presence of ACE2 coding variants and expression quantitative trait loci (eQTLs). We identified a splice site variant
(rs2285666) associated with increased ACE2 expression with an overrepresentation in SARS-CoV-2 positive patients relative to
100KGP controls (p = .015), and in hospitalised European patients relative to outpatients in intra-ethnic comparisons (p = .029). We
also compared the prevalence of 288 eQTLs, of which 23 were enriched in SARS-CoV-2 positive patients. The eQTL rs12006793 had
the largest effect size (d = 0.91), which decreases ACE2 expression and is more prevalent in controls, thus potentially reducing the
risk of COVID-19. We identified three novel nonsynonymous variants predicted to alter ACE2 function, and showed that three
variants (p.K26R, p.H378R, p.Y515N) alter receptor affinity for the viral Spike (S) protein. Variant p.N720D, more prevalent in the
European population (p < .001), potentially increases viral entry by affecting the ACE2-TMPRSS2 complex. In conclusion, the spectrum
of genetic variants in ACE2 may inform risk stratification of COVID-19 patients and could partially explain the differences in
disease susceptibility and severity among different ethnic groups.
AB - There is considerable variability in the susceptibility and progression for COVID-19 and it appears to be strongly correlated with
age, gender, ethnicity and pre-existing health conditions. However, to our knowledge, cohort studies of COVID-19 in clinically
vulnerable groups are lacking. Host genetics has also emerged as a major risk factor for COVID-19, and variation in the ACE2
receptor, which facilitates entry of the SARS-CoV-2 virus into the cell, has become a major focus of attention. Thus, we
interrogated an ethnically diverse cohort of National Health Service (NHS) patients in the United Kingdom (UK) to assess the
association between variants in the ACE2 locus and COVID-19 risk. We analysed whole-genome sequencing (WGS) data of 1,837 cases
who were tested positive for SARS-CoV-2, and 37,207 controls who were not tested, from the UK’s 100,000 Genomes Project
(100KGP) for the presence of ACE2 coding variants and expression quantitative trait loci (eQTLs). We identified a splice site variant
(rs2285666) associated with increased ACE2 expression with an overrepresentation in SARS-CoV-2 positive patients relative to
100KGP controls (p = .015), and in hospitalised European patients relative to outpatients in intra-ethnic comparisons (p = .029). We
also compared the prevalence of 288 eQTLs, of which 23 were enriched in SARS-CoV-2 positive patients. The eQTL rs12006793 had
the largest effect size (d = 0.91), which decreases ACE2 expression and is more prevalent in controls, thus potentially reducing the
risk of COVID-19. We identified three novel nonsynonymous variants predicted to alter ACE2 function, and showed that three
variants (p.K26R, p.H378R, p.Y515N) alter receptor affinity for the viral Spike (S) protein. Variant p.N720D, more prevalent in the
European population (p < .001), potentially increases viral entry by affecting the ACE2-TMPRSS2 complex. In conclusion, the spectrum
of genetic variants in ACE2 may inform risk stratification of COVID-19 patients and could partially explain the differences in
disease susceptibility and severity among different ethnic groups.
KW - ACE2
KW - COVID-19
KW - Genetics
KW - SARS-CoV-2
KW - eQTLs
KW - genetics
KW - variants
U2 - 10.3389/fgene.2022.888025
DO - 10.3389/fgene.2022.888025
M3 - Article
C2 - 35571054
SN - 1664-8021
VL - 13
JO - Frontiers in Genetics
JF - Frontiers in Genetics
M1 - 888025
ER -